Marinus down after seizure treatment fails to meet a key late-stage study goal

Marinus Pharmaceuticals

17/06/2024 12:32

** Shares of drug maker Marinus Pharmaceuticals  MRNS.O  
down 12.6% at $1.30 before the bell 
    ** Co says its intravenous treatment, for a type of seizure
known as refractory status epilepticus, failed to meet one of
the two key goals, in a late stage study 
    ** Miranus's drug ganaxolone, a neuroactive steroid, failed
to achieve statistical significance on the second endpoint of
the proportion of patients not progressing to intravenous
anesthesia versus placebo
    ** The oral version of the drug, under the brand name
Ztalmy, is approved by the U.S. FDA for treatment of seizures
associated with CDKL5 deficiency disorder, a rare genetic
epilepsy  
    ** As of last close, stock down 86.5% YTD 

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))